Trait Information | |
Identifier | MONDO_0004986 |
Description | A carcinoma that arises from epithelial cells of the urinary bladder | Trait category |
Cancer
|
Synonyms |
13 synonyms
|
Mapped terms |
6 mapped terms
|
Polygenic Score ID & Name | PGS Publication ID (PGP) | Reported Trait | Mapped Trait(s) (Ontology) | Number of Variants |
Ancestry distribution GWAS Dev Eval |
Scoring File (FTP Link) |
---|---|---|---|---|---|---|
PGS000071 (CC_Bladder) |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Bladder cancer | urinary bladder carcinoma | 15 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000071/ScoringFiles/PGS000071.txt.gz |
PGS000152 (cGRS_Bladder) |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Bladder cancer | urinary bladder carcinoma | 10 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000152/ScoringFiles/PGS000152.txt.gz |
PGS000607 (PRSWEB_PHECODE189.2_20001-1035_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Bladder cancer | urinary bladder carcinoma | 1,095,241 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000607/ScoringFiles/PGS000607.txt.gz | |
PGS000608 (PRSWEB_PHECODE189.2_C3-BLADDER_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Bladder cancer | urinary bladder carcinoma | 1,097,063 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000608/ScoringFiles/PGS000608.txt.gz | |
PGS000609 (PRSWEB_PHECODE189.2_C67_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Bladder cancer | urinary bladder carcinoma | 1,130 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000609/ScoringFiles/PGS000609.txt.gz | |
PGS000610 (PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Bladder cancer | urinary bladder carcinoma | 13 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000610/ScoringFiles/PGS000610.txt.gz | |
PGS000611 (PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Bladder cancer | urinary bladder carcinoma | 13 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000611/ScoringFiles/PGS000611.txt.gz | |
PGS000612 (PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Bladder cancer | urinary bladder carcinoma | 13 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000612/ScoringFiles/PGS000612.txt.gz | |
PGS000613 (PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Bladder cancer | urinary bladder carcinoma | 15 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000613/ScoringFiles/PGS000613.txt.gz | |
PGS000614 (PRSWEB_PHECODE189.2_UKBB-SAIGE-HRC-X189.2_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Bladder cancer | urinary bladder carcinoma | 1,119,238 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000614/ScoringFiles/PGS000614.txt.gz | |
PGS000615 (PRSWEB_PHECODE189.2_UKBB-SAIGE-HRC-X189.2_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Bladder cancer | urinary bladder carcinoma | 106 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000615/ScoringFiles/PGS000615.txt.gz | |
PGS000616 (PRSWEB_PHECODE189.2_UKBB-SAIGE-HRC-X189.2_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Bladder cancer | urinary bladder carcinoma | 24,359 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000616/ScoringFiles/PGS000616.txt.gz | |
PGS000723 (PRS_Bladder) |
PGP000135 | Jia G et al. JNCI Cancer Spectr (2020) |
Bladder cancer | urinary bladder carcinoma | 14 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000723/ScoringFiles/PGS000723.txt.gz |
PGS000782 (CC_Bladder_IV) |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Bladder cancer | urinary bladder carcinoma | 15 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000782/ScoringFiles/PGS000782.txt.gz |
PGS001807 (portability-PLR_189.2) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Bladder cancer | urinary bladder carcinoma | 291 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001807/ScoringFiles/PGS001807.txt.gz |
PGS002017 (portability-ldpred2_189.2) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Bladder cancer | urinary bladder carcinoma | 510,453 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002017/ScoringFiles/PGS002017.txt.gz |
PGS003335 (GRS18_BC) |
PGP000404 | Teleka S et al. Sci Rep (2022) |
Bladder cancer | urinary bladder carcinoma | 18 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003335/ScoringFiles/PGS003335.txt.gz |
PGS004241 (PRS12_bladder) |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Bladder cancer | urinary bladder carcinoma | 12 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004241/ScoringFiles/PGS004241.txt.gz |
PGS004687 (bladder_cancer) |
PGP000596 | Hu J et al. JNCI Cancer Spectr (2024) |
Bladder cancer | urinary bladder carcinoma | 1,077,775 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004687/ScoringFiles/PGS004687.txt.gz |
PGS Performance Metric ID (PPM) |
Evaluated Score |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|---|
PPM000191 | PGS000071 (CC_Bladder) |
PSS000110| European Ancestry| 412,602 individuals |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Reported Trait: Bladder cancer | OR: 1.3 [1.25, 1.36] | — | — | Genotyping reagent kit (GERA cohort only), genotyping array (UK Biobank only), age, sex, 10 PCs. | Results from meta-analysis of GERA and UKB |
PPM002037 | PGS000071 (CC_Bladder) |
PSS001010| European Ancestry| 391,888 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |Ext. |
Reported Trait: Incident blader cancer | HR: 1.28 [1.2, 1.37] | AUROC: 0.803 C-index: 0.813 (0.008) |
— | Age at assessment, sex, genotyping array, PCs(1-15), cigarette pack-years, smoking status(never vs. former vs. current), body mass index | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
PPM017172 | PGS000071 (CC_Bladder) |
PSS010143| European Ancestry| 424 individuals |
PGP000443 | Byrne S et al. Int J Epidemiol (2023) |Ext. |
Reported Trait: Bladder cancer | HR: 1.21 [1.1, 1.33] | — | — | age at baseline, sex (where relevant), assessment centre, 40 principal components of ancestries (PCs), Townsend Index, education, birth location, income, lifestyle index | — |
PPM000472 | PGS000152 (cGRS_Bladder) |
PSS000272| European Ancestry| 13,770 individuals |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Reported Trait: Bladder cancer | — | — | Mean realative risk: 1.04 [1.0, 1.08] Wilcoxon test (case vs. control) p-value: 0.00377 |
— | — |
PPM000483 | PGS000152 (cGRS_Bladder) |
PSS000272| European Ancestry| 13,770 individuals |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Reported Trait: Bladder cancer | — | — | Odds Ratio (OR; high vs. average risk groups): 1.58 [1.1, 2.25] | — | — |
PPM001292 | PGS000607 (PRSWEB_PHECODE189.2_20001-1035_PRS-CS_MGI_20200608) |
PSS000555| European Ancestry| 7,622 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bladder | OR: 1.096 [1.018, 1.18] β: 0.0918 (0.0377) |
AUROC: 0.531 [0.509, 0.551] | Nagelkerke's Pseudo-R²: 0.00156 Brier score: 0.0922 Odds Ratio (OR, top 1% vs. Rest): 0.671 [0.279, 1.61] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.2_20001-1035_PRS-CS_MGI_20200608 |
PPM001293 | PGS000608 (PRSWEB_PHECODE189.2_C3-BLADDER_PRS-CS_MGI_20200608) |
PSS000555| European Ancestry| 7,622 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bladder | OR: 1.084 [1.006, 1.167] β: 0.0803 (0.0377) |
AUROC: 0.521 [0.499, 0.541] | Nagelkerke's Pseudo-R²: 0.00124 Brier score: 0.0922 Odds Ratio (OR, top 1% vs. Rest): 1.53 [0.832, 2.83] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.2_C3-BLADDER_PRS-CS_MGI_20200608 |
PPM001294 | PGS000609 (PRSWEB_PHECODE189.2_C67_LASSOSUM_MGI_20200608) |
PSS000555| European Ancestry| 7,622 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bladder | OR: 1.106 [1.027, 1.191] β: 0.101 (0.0376) |
AUROC: 0.528 [0.508, 0.549] | Nagelkerke's Pseudo-R²: 0.00205 Brier score: 0.0922 Odds Ratio (OR, top 1% vs. Rest): 1.69 [0.934, 3.06] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.2_C67_LASSOSUM_MGI_20200608 |
PPM001295 | PGS000610 (PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_P_5e-08_MGI_20200608) |
PSS000555| European Ancestry| 7,622 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bladder | OR: 1.292 [1.201, 1.391] β: 0.256 (0.0375) |
AUROC: 0.572 [0.55, 0.594] | Nagelkerke's Pseudo-R²: 0.013 Brier score: 0.0917 Odds Ratio (OR, top 1% vs. Rest): 1.47 [0.779, 2.77] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_P_5e-08_MGI_20200608 |
PPM001296 | PGS000611 (PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_P_5e-08_UKB_20200608) |
PSS000576| European Ancestry| 13,530 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bladder | OR: 1.284 [1.211, 1.361] β: 0.25 (0.0298) |
AUROC: 0.567 [0.551, 0.584] | Nagelkerke's Pseudo-R²: 0.0114 Brier score: 0.0821 Odds Ratio (OR, top 1% vs. Rest): 2.66 [1.79, 3.93] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_P_5e-08_UKB_20200608 |
PPM001297 | PGS000612 (PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_PT_MGI_20200608) |
PSS000555| European Ancestry| 7,622 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bladder | OR: 1.292 [1.201, 1.391] β: 0.256 (0.0375) |
AUROC: 0.572 [0.55, 0.594] | Nagelkerke's Pseudo-R²: 0.013 Brier score: 0.0917 Odds Ratio (OR, top 1% vs. Rest): 1.47 [0.779, 2.77] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_PT_MGI_20200608 |
PPM001298 | PGS000613 (PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_PT_UKB_20200608) |
PSS000576| European Ancestry| 13,530 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bladder | OR: 1.301 [1.227, 1.379] β: 0.263 (0.0299) |
AUROC: 0.571 [0.555, 0.588] | Nagelkerke's Pseudo-R²: 0.0125 Brier score: 0.0821 Odds Ratio (OR, top 1% vs. Rest): 2.91 [1.99, 4.24] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_PT_UKB_20200608 |
PPM001299 | PGS000614 (PRSWEB_PHECODE189.2_UKBB-SAIGE-HRC-X189.2_PRS-CS_MGI_20200608) |
PSS000555| European Ancestry| 7,622 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bladder | OR: 1.087 [1.01, 1.171] β: 0.0836 (0.0377) |
AUROC: 0.525 [0.503, 0.547] | Nagelkerke's Pseudo-R²: 0.00135 Brier score: 0.0922 Odds Ratio (OR, top 1% vs. Rest): 0.675 [0.28, 1.62] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.2_UKBB-SAIGE-HRC-X189.2_PRS-CS_MGI_20200608 |
PPM001300 | PGS000615 (PRSWEB_PHECODE189.2_UKBB-SAIGE-HRC-X189.2_PT_MGI_20200608) |
PSS000555| European Ancestry| 7,622 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bladder | OR: 1.084 [1.007, 1.167] β: 0.0809 (0.0376) |
AUROC: 0.519 [0.498, 0.541] | Nagelkerke's Pseudo-R²: 0.00137 Brier score: 0.0922 Odds Ratio (OR, top 1% vs. Rest): 0.788 [0.35, 1.78] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.2_UKBB-SAIGE-HRC-X189.2_PT_MGI_20200608 |
PPM001301 | PGS000616 (PRSWEB_PHECODE189.2_UKBB-SAIGE-HRC-X189.2_LASSOSUM_MGI_20200608) |
PSS000555| European Ancestry| 7,622 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bladder | OR: 1.138 [1.057, 1.225] β: 0.129 (0.0376) |
AUROC: 0.538 [0.517, 0.557] | Nagelkerke's Pseudo-R²: 0.00345 Brier score: 0.0921 Odds Ratio (OR, top 1% vs. Rest): 0.983 [0.459, 2.11] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.2_UKBB-SAIGE-HRC-X189.2_LASSOSUM_MGI_20200608 |
PPM001653 | PGS000723 (PRS_Bladder) |
PSS000853| European Ancestry| 400,812 individuals |
PGP000135 | Jia G et al. JNCI Cancer Spectr (2020) |
Reported Trait: Incident bladder cancer | — | AUROC: 0.583 [0.559, 0.607] | — | Genotyping array | — |
PPM002053 | PGS000782 (CC_Bladder_IV) |
PSS001010| European Ancestry| 391,888 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Reported Trait: Incident blader cancer | HR: 1.3 [1.22, 1.39] | AUROC: 0.804 C-index: 0.814 (0.008) |
R²: 0.628 | Age at assessment, sex, genotyping array, PCs(1-15), cigarette pack-years, smoking status(never vs. former vs. current), body mass index | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
PPM009359 | PGS001807 (portability-PLR_189.2) |
PSS009277| European Ancestry| 19,893 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): 0.0197 [0.0058, 0.0336] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009360 | PGS001807 (portability-PLR_189.2) |
PSS009051| European Ancestry| 4,121 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): 0.0266 [-0.004, 0.0572] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009361 | PGS001807 (portability-PLR_189.2) |
PSS008605| European Ancestry| 6,645 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): 0.0169 [-0.0072, 0.041] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009362 | PGS001807 (portability-PLR_189.2) |
PSS008382| Greater Middle Eastern Ancestry| 1,195 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): 0.0347 [-0.0225, 0.0917] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009363 | PGS001807 (portability-PLR_189.2) |
PSS008159| South Asian Ancestry| 6,301 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): -0.0016 [-0.0263, 0.0231] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009365 | PGS001807 (portability-PLR_189.2) |
PSS007728| African Ancestry| 2,471 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): -0.0043 [-0.0439, 0.0353] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009366 | PGS001807 (portability-PLR_189.2) |
PSS008831| African Ancestry| 3,914 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): 0.0359 [0.0045, 0.0673] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009364 | PGS001807 (portability-PLR_189.2) |
PSS007946| East Asian Ancestry| 1,803 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): 0.0321 [-0.0144, 0.0784] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM011010 | PGS002017 (portability-ldpred2_189.2) |
PSS009277| European Ancestry| 19,893 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): 0.0181 [0.0042, 0.032] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM011011 | PGS002017 (portability-ldpred2_189.2) |
PSS009051| European Ancestry| 4,121 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): 0.0333 [0.0026, 0.0638] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM011012 | PGS002017 (portability-ldpred2_189.2) |
PSS008605| European Ancestry| 6,645 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): 0.0144 [-0.0097, 0.0385] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM011013 | PGS002017 (portability-ldpred2_189.2) |
PSS008382| Greater Middle Eastern Ancestry| 1,195 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): 0.0296 [-0.0276, 0.0867] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM011014 | PGS002017 (portability-ldpred2_189.2) |
PSS008159| South Asian Ancestry| 6,301 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): 0.0047 [-0.02, 0.0294] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM011015 | PGS002017 (portability-ldpred2_189.2) |
PSS007946| East Asian Ancestry| 1,803 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): 0.0257 [-0.0208, 0.072] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM011017 | PGS002017 (portability-ldpred2_189.2) |
PSS008831| African Ancestry| 3,914 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): 0.0257 [-0.0057, 0.0571] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM011016 | PGS002017 (portability-ldpred2_189.2) |
PSS007728| African Ancestry| 2,471 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of bladder | — | — | Partial Correlation (partial-r): -0.0071 [-0.0467, 0.0325] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM016166 | PGS003335 (GRS18_BC) |
PSS010054| European Ancestry| 10,576 individuals |
PGP000404 | Teleka S et al. Sci Rep (2022) |
Reported Trait: Urothelial carcinoma | HR: 1.27 [1.15, 1.4] | — | — | Smoking, BMI, education, and physical activity | — |
PPM016167 | PGS003335 (GRS18_BC) |
PSS010054| European Ancestry| 10,576 individuals |
PGP000404 | Teleka S et al. Sci Rep (2022) |
Reported Trait: Non-aggressive urothelial carcinoma | HR: 1.34 [1.18, 1.52] | — | — | Smoking, BMI, education, and physical activity | — |
PPM016168 | PGS003335 (GRS18_BC) |
PSS010054| European Ancestry| 10,576 individuals |
PGP000404 | Teleka S et al. Sci Rep (2022) |
Reported Trait: Aggressive urothelial carcinoma | HR: 1.19 [1.0, 1.42] | — | — | Smoking, BMI, education, and physical activity | — |
PPM016169 | PGS003335 (GRS18_BC) |
PSS010054| European Ancestry| 10,576 individuals |
PGP000404 | Teleka S et al. Sci Rep (2022) |
Reported Trait: Urothelial carcinoma x systolic blood pressure interaction | HR: 1.55 [1.14, 2.1] | — | — | Smoking, BMI, physical activity and level of education | — |
PPM016170 | PGS003335 (GRS18_BC) |
PSS010054| European Ancestry| 10,576 individuals |
PGP000404 | Teleka S et al. Sci Rep (2022) |
Reported Trait: Non-aggressive urothelial carcinoma x systolic blood pressure interaction | HR: 1.59 [1.07, 2.35] | — | — | Smoking, BMI, physical activity and level of education | — |
PPM016171 | PGS003335 (GRS18_BC) |
PSS010054| European Ancestry| 10,576 individuals |
PGP000404 | Teleka S et al. Sci Rep (2022) |
Reported Trait: Aggressive urothelial carcinoma x systolic blood pressure interaction | HR: 1.72 [1.03, 2.87] | — | — | Smoking, BMI, physical activity and level of education | — |
PPM016172 | PGS003335 (GRS18_BC) |
PSS010054| European Ancestry| 10,576 individuals |
PGP000404 | Teleka S et al. Sci Rep (2022) |
Reported Trait: Urothelial carcinoma x diastolic blood pressure interaction | HR: 1.45 [1.09, 1.92] | — | — | Smoking, BMI, physical activity and level of education | — |
PPM016173 | PGS003335 (GRS18_BC) |
PSS010054| European Ancestry| 10,576 individuals |
PGP000404 | Teleka S et al. Sci Rep (2022) |
Reported Trait: Non-aggressive urothelial carcinoma x diastolic blood pressure interaction | HR: 1.54 [1.07, 2.22] | — | — | Smoking, BMI, physical activity and level of education | — |
PPM016174 | PGS003335 (GRS18_BC) |
PSS010054| European Ancestry| 10,576 individuals |
PGP000404 | Teleka S et al. Sci Rep (2022) |
Reported Trait: Aggressive urothelial carcinoma x diastolic blood pressure interaction | HR: 1.38 [0.82, 2.31] | — | — | Smoking, BMI, physical activity and level of education | — |
PPM020298 | PGS004241 (PRS12_bladder) |
PSS011328| European Ancestry| 133,830 individuals |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Reported Trait: Bladder cancer | HR: 1.41 [1.09, 1.83] | — | — | first 10 genetic principal components | — |
PPM020308 | PGS004241 (PRS12_bladder) |
PSS011329| European Ancestry| 115,207 individuals |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Reported Trait: Bladder cancer | HR: 1.28 [1.12, 1.48] | — | — | first 10 genetic principal components | — |
PPM020872 | PGS004687 (bladder_cancer) |
PSS011431| European Ancestry| 40,771 individuals |
PGP000596 | Hu J et al. JNCI Cancer Spectr (2024) |
Reported Trait: Bladder cancer | — | AUROC: 0.5582 | — | — | — |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS000555 | PheCode:189.2; ICD9CM:188.0, 188.1, 188.2, 188.3, 188.4, 188.5, 188.6, 188.7, 188.8, 188.9, 233.7, 236.7, 239.4, V10.51; ICD10CM:C67, C67.0, C67.1, C67.2, C67.3, C67.4, C67.5, C67.6, C67.7, C67.8, C67.9, D09.0, D41.4, D49.4 | — | [
|
— | European | — | MGI | — |
PSS010054 | — | — | [ ,
100.0 % Male samples |
Mean = 59.0 years | European | — | MDC | — |
PSS011328 | — | — | 133,830 individuals, 0.0 % Male samples |
— | European (British) |
— | UKB | — |
PSS011329 | — | — | 115,207 individuals, 100.0 % Male samples |
— | European (British) |
— | UKB | — |
PSS011431 | — | — | [
|
— | European | — | UKB | — |
PSS000576 | PheCode:189.2; ICD9:233.7, 236.7, 239.4; ICD10:C67.0, C67.1, C67.2, C67.3, C67.4, C67.5, C67.6, C67.7, C67.8, C67.9, D09.0, D41.4 | — | [
|
— | European | — | UKB | — |
PSS009051 | — | — | 4,121 individuals | — | European | Poland (NE Europe) | UKB | — |
PSS008159 | — | — | 6,301 individuals | — | South Asian | India (South Asia) | UKB | — |
PSS008831 | — | — | 3,914 individuals | — | African unspecified | Nigeria (West Africa) | UKB | — |
PSS007946 | — | — | 1,803 individuals | — | East Asian | China (East Asia) | UKB | — |
PSS000853 | Data and diagnoses on site-specific incident cancers were provided by the National Health Service Information Centre for participants from England and Wales (follow-up through March 31, 2016) and by the NHS Central Register Scotland for participants from Scotland (follow-up through October 31, 2015). Cancers were coded by the International Classification of Diseases, Ninth Revision (ICD-9) or the International Classification of Diseases, Tenth Revision (ICD-10). Bladder cancer =(ICD-9 = 188 or ICD-10 = C67). | Median = 5.8 years | [ ,
46.5 % Male samples |
— | European | — | UKB | — |
PSS000272 | Primary tumor samples from TCGA | — | [
|
Mean = 69.0 years Sd = 10.0 years |
European | — | TCGA | — |
PSS000272 | — | — | [
|
— | European | — | eMERGE | — |
PSS010143 | — | — | [
|
— | European | — | UKB | — |
PSS008605 | — | — | 6,645 individuals | — | European | Italy (South Europe) | UKB | — |
PSS007728 | — | — | 2,471 individuals | — | African American or Afro-Caribbean | Carribean | UKB | — |
PSS001010 | Individuals with at least one recorded incident diagnosis of a borderline, in situ, or malignant primary cancer were defined as cases. | — | [
|
— | European | — | UKB | — |
PSS000110 | Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 29010 | — | [ ,
46.0 % Male samples |
Mean = 58.0 years | European | — | GERA, UKB | — |
PSS009277 | — | — | 19,893 individuals | — | European | UK (+ Ireland) | UKB | — |
PSS008382 | — | — | 1,195 individuals | — | Greater Middle Eastern (Middle Eastern, North African or Persian) | Iran (Middle East) | UKB | — |